Identifying aneuploidy-tolerating genes by Simon, Judith Elisabeth
  
 University of Groningen
Identifying aneuploidy-tolerating genes
Simon, Judith Elisabeth
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2018
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Simon, J. E. (2018). Identifying aneuploidy-tolerating genes. [Groningen]: Rijksuniversiteit Groningen.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the




CINcere modelling: What have mouse models 
for chromosome instability taught us?
Judith E. Simon&1, Bjorn Bakker&1 and Floris Foijer|1
1European Research Institute for the Biology of Ageing (ERIBA), University of Groningen, University 
Medical Center Groningen,9713 AV Groningen, the Netherlands
&These authors contributed equally 
|Senior author
This chapter is based on: 
Recent Results Cancer Res. 2015;200:39-60
10 | Chapter 1
ABSTRACT
Chromosome instability (CIN) is a process leading to errors in chromosome segregation 
and results in aneuploidy, a state wherein cells have an abnormal number of chromosomes. 
CIN is a hallmark of cancer, and furthermore linked to ageing and age-related diseases 
such as Alzheimer’s. Various mouse models have been developed that model CIN to 
study the relationship between CIN, ageing and cancer. While these models reveal only a 
modest contribution of CIN to the initiation of cancer, they also clearly show that CIN is 
a powerful accelerator of cancer in a predisposed background. Additionally, CIN appears 
to provoke premature ageing in some of the CIN models. In this review, we discuss the 
phenotypes of the various mouse models, what we have learned from them, and which 
questions still need to be addressed. 
ABSTRACT
Chromosome instability (CIN) is a process leading to errors in chromosome segre-
gation and results in aneuploidy, a state in which cells have an abnormal number of 
chromosomes. CIN is a hallmark of cancer, and furthermore linked to ageing and 
age-related diseases such as Alzheimer’s. Various mouse models have been devel-
oped that model CIN to study the relationship between CIN, ageing and cancer. 
While these models reveal only a modest contribution of CIN to the initiation of 
cancer, they also clearly show that CIN is a powerful accelerator of cancer in a pre-
disposed background. Other than cancer, CIN also appears to provoke premature 
ageing in some of the CIN models. In this review, we discuss the phenotypes of the 
various available mouse models, what we have learnt so far, and importantly, also 
which questions still need addressing. 
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INTRODUCTION
Chromosome instability and aneuploidy
During each cell division our genetic code is replicated, followed by the symmetrical 
segregation of all chromosomes into the emerging daughter cells. Cancer cells occasionally 
mis-segregate their chromosomes, a process known as chromosome instability (CIN), 
leading to cells with abnormal numbers of chromosomes, a state defined as aneuploid. In 
addition to whole chromosome abnormalities, CIN can also lead to structural abnormalities 
such as amplifications, deletions or translocations, either through defects in the DNA 
damage machinery or as a direct result of chromosome mis-segregation events1. Although 
numerical and structural abnormalities frequently coincide, in this review we will focus 
on how mouse models have contributed to our understanding of the consequences of 
whole chromosome instability.
David von Hansemann was the first to report abnormal chromosome numbers in 
carcinoma samples in 1890, long before the relationship between chromosomes and the 
genetic code had been established. Early in the 20th century, Theodor Boveri showed that 
aneuploidy leads to abnormal development or even death by injecting two sperm instead 
of one into sea urchin embryos. These observations led to the hypothesis that aneuploidy 
can lead to cancer or developmental defects2–4. Since then, many studies confirmed that 
CIN is a hallmark of human malignancies, affecting 2 out of 3 cancers5. More recently, 
aneuploidy has also been associated with ageing and age-related diseases6. For instance, 
trisomy for chromosome 21 is frequently found in plaques in Alzheimer patients’ brains7. 
Conversely, people with Down syndrome develop early onset Alzheimer’s disease8, 
further emphasizing the relationship between trisomy 21 and neurodegenerative disease. 
Although CIN has been associated with cancer for more than a century, we are only 
beginning to understand the consequences of CIN and aneuploidy at the cellular and 
molecular levels. CIN is believed to accelerate the evolution of cancer cells by facilitating 
gain of oncogenes and loss of tumour suppressor genes. Paradoxically, when modelled in 
yeast strains9 or mouse embryonic fibroblasts (MEFs)10, aneuploidy appears to decrease 
rather than enhance cell proliferation, suggesting that cancer cells find ways to cope with 
the adverse effects of aneuploidy. However, as transformation of aneuploid cells into 
aneuploid cancer cells can only occur in vivo by definition, animal models for CIN are 
essential to solve this paradox.
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Provoking CIN in vivo
Several processes that safeguard correct chromosome segregation have been targeted to 
engineer mouse models for CIN. Figure 1 shows a schematic overview of a large number 
of genes that have been targeted for this purpose. One of the first models specifically 
designed to study the in vivo consequences of CIN is the Mad2 knockout mouse, 
targeting the spindle assembly checkpoint (SAC)11. The SAC prevents mis-segregation of 
chromosomes by inhibiting metaphase to anaphase progression until all chromosomes are 
properly attached to kinetochores in a bi-oriented fashion. Defects of the SAC therefore 
result in flawed chromosome segregation, which makes the SAC an attractive target to 
model CIN in vivo. A second means to induce CIN in vivo is by interfering with kinetochore 
integrity, a protein structure that connects the centromeric DNA to the mitotic spindle. 
This has been done by removing structural components of the kinetochore (e.g. CenpB, 
CenpC) or alternatively by stabilizing kinetochore-microtubule attachments through e.g. 
overexpressing Mad2 or Hec112,13. Centrosomes are the microtubule-organizing centres 
in the cell from which the mitotic spindle emanates14,15. Abnormal centrosome numbers 
can either result in multipolar divisions or, when supranumeral centrosomes cluster, 
predispose for lagging chromosomes in mitosis16. Therefore, a third way to provoke CIN 
in vivo is by inducing centrosome amplification, e.g. through overexpression of Plk417,18. 
A fourth approach to induce CIN in vivo is by disrupting the cohesion complex, a ring-
like structure that holds the sister chromatids together during interphase. Cohesion defects 
have been modelled by abrogating components of the cohesion complex (e.g. SA1), but 
also by deregulating upstream players such as pRb19–21. Similarly, various other genes 
have been knocked out in the mouse that indirectly affect chromosome segregation.
In vivo consequences of CIN
In the last two decades, a large number of mouse models for chromosome instability have 
been engineered. Hereunder, we summarize the findings from these models asking the 
following questions:
1) Is CIN a bona fide instigator of cancer?
2) Which genes collaborate with CIN in vivo to convert aneuploid cells into aneuploid 
cancer cells? 
3) What are the other consequences of CIN in vivo? 










































Figure 1 Schematic overview of various genes targeted to provoke CIN in vivo.
Can CIN initiate cancer? 
CIN has detrimental consequences for cells grown in vitro10,22,23, yet, two out of three 
human tumours are aneuploid5,24. This raises the question whether CIN is an initiating 
factor in cancer, a facilitator or merely a side effect of tumourigenesis. In the vast majority 
of all CIN-inducing mouse models (see Figure 1), full inactivation of the targeted genes 
resulted in early embryonic lethality. Although the time of embryonic death varied 
between genotypes (Table 1), embryos were typically lost before embryonic day 10, 
likely the result of aneuploidy in the inner cell mass of the developing embryos11,24–27. To 
circumvent embryonic lethality, phenotypes of heterozygous mice were monitored, or in 
some cases conditional alleles were engineered. Even though tumour phenotypes have 
been reported for many of these models (Table1), tumour incidence is relatively low, with 
fewer than 50% of the mice developing cancer. Moreover, tumours only arise late in the 
life of the mice, with latencies typically ranging from 12 to 24 months Table 1. The most 
frequent pathologies observed include lymphoma, lung and liver tumours. Furthermore, 
not all models develop spontaneous tumours, such as in case of the Bub family members 
(Bub1, Bub3, Rae128–33). There is no clear correlation between the severity of the tumour 
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phenotypes and the mechanism that drove CIN in the mice (i.e. SAC mutation, cohesion 
defects, centrosome abnormalities etc.). Expression levels of the CIN-provoking genes, 
on the other hand, appear to be a better predictor of tumour incidence: phenotypes were 
most severe in cases where CIN-driving proteins were overexpressed to high levels (e.g. 
Mad2, Cyclin B1, Cyclin B2, Hec1, Plk413,17,34,35) possibly because the relative effect on 
protein expression (several folds overexpression) was more dramatic than in heterozygous 
mice, where protein levels were typically reduced by ~50%. However, tumour latency is 
high in these models as well, suggesting that additional mutations must be required for 
aneuploid cells to become malignant.
Does CIN predispose cells to cancer?
Exposure to carcinogens is a powerful tool to assess tumour predisposition in vivo. 
Given the relatively weak tumour phenotypes of the mouse models described above, 
various CIN models were exposed to carcinogens (Table 1) to assess whether CIN 
is a powerful collaborator in transforming cells. Indeed, carcinogens aggravated the 
tumour phenotypes of some of the CIN mice, more than their control counterparts. For 
instance, when Mad1 heterozygous mice were treated with vincristine (a microtubule-
depolymerizing agent) 40% of the mice developed, mostly lung tumours, while no 
tumours were detected in control-treated mice36. Likewise, carcinogens (NMBA or 
DMBA) accelerated tumourigenesis in Lzts1-deficient and Chfr-deficient mice, relative 
to control mice37,38. Furthermore, even in CIN mice without a tumour phenotype (e.g. 
Bub1+/-, Bub3+/-, Rae1+/- and Bub3+/- Rae1+/-), DMBA treatment had a stronger tumour 
promoting effect in these CIN mice than on wildtype mice31,32. As carcinogens reduce 
tumour latency and increase tumour incidence in a CIN background, these experiments 
also indicate that additional mutations are required for a CIN cell to transform into a 
malignant cell. 
Which genes collaborate with CIN in cancer? 
To test which genetic alterations collaborate with CIN in tumourigenesis, various CIN 
models were crossed into cancer-predisposed backgrounds. For example, when CIN 
was combined with p53 heterozygosity, (Bub1, Espl1, Mps133,39,40) tumour incidence 
dramatically increased while tumour latencies decreased. In all reported cases, tumours 
had lost the remaining p53 wild type allele, indicating that full p53 loss and CIN synergize 
in tumourigenesis33,46. However, since CIN also further increased tumour incidence of 
p53null mice, CIN must have facilitated cancer formation through additional genomic 
alterations as well. Additionally, CIN provoked by Bub1 hypomorphic alleles or Cyclin 
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B1 overexpression have been shown to accelerate tumours in a Apcmin background33,35. 
However, in other tumour predisposed backgrounds (e.g. pRb or Pten heterozygosity) 
CIN has no effect on tumour incidence33.
CIN as a tumour suppressor
In some cases CIN can also act in a tumour suppressive manner. For instance, CIN driven 
by SA1 heterozygosity delays 3-methyl-colanthrene (3-MC)-induced fibrosarcoma and 
diethyl-nitrosamine (DEN)-induced liver tumours41. Similarly, while Cdh1+/- mice and 
CenpE+/- mice are more susceptible to spontaneous tumours, they are more resistant to 
carcinogenic insults than their wild type counterparts42,43. Furthermore, CIN can also 
delay tumourigenesis in some genetically predisposed models, for instance by delaying 
p19Arf or Pten loss-driven tumours33,43. Why then is CIN tumour promoting in one setting, 
but tumour suppressive in another? The answer might lie in the levels of CIN. CIN is 
quite toxic and provokes an ‘aneuploidy stress’ response in untransformed cells9,10,23,44. 
However, aneuploid cancer cells also exhibit this stress response45,46, suggesting that 
aneuploid cancer cells still suffer from the disadvantageous effects of CIN. Therefore, 
the levels of CIN occurring in premalignant cells could be a determining factor for the 
outcome. The fact that p19Arf loss provokes aneuploidy itself fits with this hypothesis, as 
CenpE heterozygosity would exacerbate CIN to a level that is toxic for cancer cells47. 
However, further experiments are required to determine at what level CIN is beneficial 
for cancer cells and at what level the balance is tipped. 
What other phenotypes are provoked by CIN?
There is increasing evidence that aneuploidy also occurs in untransformed tissues, with 
liver being the most well-known example. Up to half of both human and murine hepatocytes 
are aneuploid48,49, but it is unclear why hepatocytes evolved to become aneuploid. One 
suggestion is that particular karyotypes are selected for during hepatotoxic insults, 
making the hepatocytes more resistant to injury48. Other studies quantified over 30% of 
normal human neuroblasts to be aneuploid50,51, which has been suggested to contribute to 
the plasticity of neurons52. However, when provoked in a random fashion, CIN appears 
to mostly have disadvantageous effects on brain function, as mice heterozygous for 
Cdh1 exhibit defects in neuromuscular coordination and learning42. The interfollicular 
epidermal cells in mouse skin on the other hand appear to cope surprisingly well with 
CIN, as they tolerate full abrogation of the SAC provoked by Mad2 loss, which results 
in dramatic aneuploidy44. The hair follicle stem cells that reside in the same compartment 
do not cope at all and disappear, resulting in mice with functional skin but without hair44. 
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Together these data clearly indicate that CIN is tolerated by some cell lineages but not 
others, underscoring the importance of in vivo modelling.
Linking ageing and CIN in vivo 
Ageing is the time-dependent functional decline in the fitness of cells, organs and 
organisms. A common hallmark of ageing is genomic instability, as exemplified by 
genetic alterations in old blood cells53,54. Some of the CIN mouse models also suggest a 
role for aneuploidy in ageing. For instance, BubR1 hypomorphic mice are not only prone 
to severe aneuploidization, but also display progeroid pathologies. Similar to BubR1, 
combined Bub3/Rae1 haploinsufficiency also results in a premature ageing phenotype, 
albeit less severe than the BubR1 hypomorph31, MEFs isolated from BubR1 hypomorphic 
mice express various ageing-associated markers such as p53, p21, p19Arf and p16Ink4a. 
Interestingly, when p16Ink4a positive cells are killed in vivo using a p16Ink4a-promotor 
regulated suicide construct, ageing pathologies induced by a reduction of BubR1 protein 
levels are dramatically delayed55. The pathologies observed in BubR1 hypomorphic mice 
mimic those of patients with multi-variegated aneuploidy (MVA), a disease that frequently 
coincides with mutations in BUB1B, the gene encoding BUBR156–58. Furthermore, BubR1 
expression levels decline with age providing further evidence for a role of BubR1 in 
ageing55 of mice. Even more striking, when BubR1 is overexpressed, a dose-dependent 
delay in the onset of ageing is observed, as well as protection against developing 
chemically-induced tumours59. As discussed above, in most tested cases overexpression 
of CIN-controlling proteins increases CIN and predisposes for cancer13,34,60. Apparently 
BubR1 is the exception that forms the rule, but future work should reveal whether BubR1 
has a unique role in the SAC or whether it has additional roles that can explain the 
beneficial effects of an overdose of BubR1.
What have we learnt from modelling CIN in the mouse so far?
As most tumours are aneuploid to some extent, CIN makes an attractive target for 
therapy. Therefore, understanding how CIN is signalled is crucial. A large number of 
mouse models have been engineered over the last 15 years specifically for this purpose, 
with a wide variety of phenotypes summarized in Table 1. Even though many of the 
targeted genes will have other roles in addition to safeguarding faithful chromosome 
segregation, some common conclusions can be drawn from the cumulative data. The 
first important conclusion is that CIN alone is not sufficient for efficient tumourigenesis 
and that CIN alone mostly has disadvantageous effects on cell proliferation. This has 
important implications for therapy targeting aneuploid cancer, as discussed below. A 
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second conclusion is that CIN facilitates tumourigenesis efficiently in some tumour-
predisposed backgrounds, chemical or genetic. However, when CIN is aggravated and 
becomes too severe, it can actually suppress tumour formation in the mouse, which can 
also be exploited in cancer therapy. A third and perhaps the most important conclusion is 
that several unaddressed questions remain before we can develop therapeutic strategies 
targeting aneuploid cell progeny, some of which are discussed below. Although all 
models discussed here were designed to study the consequences of CIN in vivo, the 
majority mimic a situation that is not typically found in human cancers, as loss of genes 
that regulate chromosome segregations are rarely lost in human cancer26,61. Even though 
these models mimic chromosome mis-segregation and its consequences, overexpression 
of CIN-modulating genes is more common (e.g. Mad2 overexpression, which is seen in 
many tumours34,62). Possibly, mimicking the CIN-provoking mutations that are found in 
human cancers would result in a physiologically more relevant CIN level, thus adding to 
our understanding of CIN and its role in tumourigenesis.
Questions that need addressing
Which mutations make an aneuploid cell an aneuploid cancer cell?
Some tumour suppressor genes, (e.g. p53) were found to accelerate the malignant 
transformation of aneuploid cells, but the mechanism behind this collaboration remains 
unclear. As CIN alone is a poor initiator of cancer, pathways that convert aneuploid cells 
to aneuploid cancer cells will be important therapeutic targets. So far, CIN-collaborating 
genes were picked in an ‘educated guess’ approach. However, to identify in an unbiased 
fashion the pathways that convert CIN cells into CIN cancer cells, (in vivo) genetic 
screens are required. 
At what rate is CIN tumourigenic and at what levels tumour suppressive?
The effects of CIN across the various mouse models are diverse, but it is unclear why. It 
is inevitable that the levels of CIN are different among the various CIN models, but there 
is no clear correlation between the levels of aneuploidy and the resulting phenotype based 
on the available data. However, as the level of CIN might determine whether tumours 
are promoted or are suppressed47, high resolution quantification of CIN will be crucial 
when targeted in therapy. Furthermore, even though aneuploidy is a hallmark of cancer, 
the actual rates of chromosome mis-segregation (i.e. the CIN rates) in human cancer 
are unknown. To quantify these, primary (tumour) cells need to be fully karyotyped at 
the single cell level at various stages. So far, most studies have relied on metaphase-
spread based (spectral) karyotyping using dividing cell populations, such as primary 
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MEFs or tumour cell lines. However, this technique cannot be applied to most primary 
tumour cells as they do not divide frequently63,64. A new, but costly approach to quantify 
karyotypes of single cells is next-generation sequencing (NGS). However, to quantify 
aneuploidy full coverage (or even multiple coverage) per cell is not a requirement. 1-2% 
coverage per cell will be sufficient to quantify chromosome numbers for an individual 
cell, allowing sequencing libraries of many cells to be pooled in each sequencing lane. 
Single-cell karyotyping will allow us to faithfully measure in vivo mis-segregation rates 
(i.e. CIN) by assessing subtle karyotype differences between cells within one tumour 
(karyotype heterogeneity). Such technology will allow us to determine at which rate CIN 
is tumourigenic or tumour suppressive in mouse models and what the CIN rates are in 
human primary tumours. 
What determines the tissue-specific response to CIN? 
There is a marked difference as to how cell lineages respond to CIN. For instance, CIN is 
highly toxic to embryonic stem cells65, but quite well tolerated by interfollicular epidermal 
cells44, hepatocytes and possibly neurons49–52. As of yet, it remains unclear what determines 
this differential response. Possibly, some cell lineages such as stem cells, induce a stronger 
stress response upon aneuploidy, resulting in apoptosis or differentiation. Alternatively, 
aneuploidy-tolerating cells spend more time in pro-metaphase and therefore have more 
time to correct improper kinetochore-microtubule attachments, thus reducing the mis-
segregation rates and therefore reducing aneuploidy to tolerable levels. Indeed some cell 
types tolerate at least some aneuploidy including neurons and hepatocytes. However, 
further in vivo experiments are required to assess which molecular pathways make up 
the response to aneuploidy at the tissue level and how the differential wiring of these 
pathways in different cell lineages determines the fate of aneuploid cells. 
What are the molecular mechanisms that explain the link between CIN and ageing?
Some of the CIN mouse models exhibit a premature ageing phenotype, most clearly 
knockout models of Bub family proteins (BubR1, Bub3/Rae1)31,66. Conversely, BubR1 
transgenic mice show increased lifespan, clearly implicating BubR1 with ageing59. This 
data, together with the observation that BubR1 expression decreases with ageing in wild 
type animals31,66, suggest that CIN may play a role in natural ageing. Why were phenotypes 
only described for Bub protein members? Possibly, (subtle) signs of premature ageing 
were overlooked in other CIN models, as these models were developed specifically to 
study the relationship between CIN and cancer and not ageing67. Indeed, a more detailed 
analysis of transcriptomes of Mad2null epidermal cells suggests an ageing-like response 
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in murine skin following SAC abrogation44, suggesting that CIN indeed provokes a 
premature ageing response in untransformed tissue. However, more detailed and high 
resolution mapping of CIN in ageing human tissues is required to confirm physiological 
relevance for a potential link between CIN and ageing. When this link is confirmed, 
the underlying molecular mechanisms that link CIN and ageing should be elucidated, 
employing exciting and possibly new, more human relevant CIN mouse models. 
What is the potential of CIN-targeting therapy? 
Aneuploidy is a hallmark of cancer and selectively killing aneuploid cells would therefore 
be a powerful means to treat cancer. The various mouse models for CIN have revealed 
that there are three possible outcomes for aneuploid cell progeny depending on the tissue 
affected: 1) cell death (e.g. in case of hair follicle stem cells), 2) cellular senescence 
(evidenced by premature ageing and upregulation of the senescence marker p16Ink4a 
and 3) tolerance of aneuploidy (Figure 2). The latter outcome is the most dangerous, as 
proliferating aneuploid cells can further evolve into aneuploid cancer cells. Therefore, 
to target aneuploid cancer, those cells that tolerate aneuploidy will need to be forced 
to either commit suicide or become senescent. There are multiple ways as to how such 
therapy could work, ranging from broad-spectrum to highly ‘personalized’ therapies. As 
discussed above, too much CIN is detrimental to cells47. Therefore, further increasing 
CIN in aneuploid tumours could be a broad-spectrum way to target aneuploid cancer 
cells. Indeed, mild CIN renders cells more sensitive to therapeutics that exacerbate CIN 
such as low doses taxol68. However, the inherent risk to this therapy is that untransformed 
(non-CIN) cells will also be exposed to CIN and might convert into a new CIN tumour 
over time. A second approach of targeting CIN cells is by modulating the pathways that 
regulate cell fate following aneuploidization. In this approach, the pathways that result in 
cell death of (embryonic) stem cells following CIN are artificially activated in aneuploid 
cancer cells, resulting in cancer cell death. However, before feasibility of such therapy 
can be assessed, CIN-responsive pathways need to be mapped first. Instead of targeting 
aneuploidy-signalling pathways, therapy can also target the downstream consequences 
of CIN. For instance, one common response to aneuploidy is a deregulation of cellular 
metabolism, which affects untransformed cells as well as cancer cells10,22,46. The first 
proof of principle evidence for such therapy is just emerging. A recent study shows that 
the energy stress inducer AICAR and the Hsp90 inhibitor 17-AAG can selectively kill 
aneuploid (cancer) cells by enhancing aneuploidy-induced stress69. The next step to this 
will be to test whether this is also effective in vivo. A fourth ‘personalised medicine’ 
approach to tackle aneuploid cancer is by targeting the mutation that is driving CIN. 
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One candidate for such therapy is Hec1, as it is frequently overexpressed in a variety of 
cancers. Indeed, inhibition of the Hec1/Nek2 pathway results in reduced tumour growth 
in a xenograft mouse model70, providing proof of principle evidence for this approach. 
Similarly, gene products that collaborate with CIN in transformation can be targeted 
using molecular therapy. For the latter, we first need to identify candidate targets, for 
instance in in vivo genetic screens. However, for molecular therapy full sequencing of the 
tumour is a requirement. As sequencing costs are rapidly decreasing and the number of 
specific pathway inhibitors are rapidly increasing, this approach might become feasible 
in the near future.
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Figure 2 Flowchart summarizing the in vivo consequences of CIN and therapeutic promise.
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Table 1 List of various mouse models engineered to provoke CIN in vivo, with phenotypes and observed aneuploidy levels 
in vivo and in vitro where quantified.
Group Gene -/- +/- Cancer predisposed 
(chemical or genetic collaboration)






















AuroraB EL >60%; 24 mo Tumour suppression upon DMBA+T-PA-induced (not sig.) ND ND
60
Bub1 EL (E6.5) VNODD DMBA-induced -57%, p53+/-; 16.6 mo ND ND
32,33
Bub1 hypomorph n/a 50%; 12 mo 78%, p53+/-; 12 mo ND 15% (seg. defects) 32,33
Bub3 EL (E6.5) VNODD DMBA-induced 10% (splenocytes) 20% 28,29,31,71
Bub3; Rae1 ND VNODD DMBA-induced 40% (splenocytes) 40% 29,31
BubR1 EL (E6.5) VNODD DMBA-induced Polyploidy in megakaryocytes 15% Yes 30,66
BubR1 hypomorph n/a Premature ageing DMBA- & azoxymethane-induced 30% (splenocytes) 35% Yes (MVA) 66




>75%; (lung, lymphoma, 
liver, lipoma)
~80%, APC+/min; 40%
(WT comparable; skin), 
DMBA-treatment
hi 20%, lo 12% (splenocytes) 31% (ctrl. 15%)  (Nam and van Deursen, 2014)
Cdc20 AAA mutant 
(does not bind to Mad2)
EL 
(E12.5) 50%; 24 mo ND 35% (Cdc20
AAA/+, splenocytes) 28% (Cdc20




17% females – (mammary);
mild brain abnormalities 
and altered behaviour
Tumour suppression upon TPA/DMBA 
treatment ND Increased (not quantified)
42
CENPE EL (<E7.5)
20% (lung, spleen); 19-
21 mo
Tumour suppression upon DMBA 
treatment or p19Arf loss 40% (splenocytes) 20% (up to 70% at high passage)
43,73
Mad1 EL 20% (lung); 18-20 mo Vinicristine-induced ND 10% 36
Mad2 EL 30% (lung); 18 mo ND ND 55% 11,74
Mad2 overexpression n/a 50% (lymphomas, lung & liver); 20 mo DMBA-induced Aneuploid tumours (not quantified) 50% Yes
34
Mps1 (T-cell restricted) VVNOD ~50% (lymphoma) 17 mo 100%, p53+/-; 5 mo >90% of cells aneuploid ND (Foijer et al., 2014)
Rae1 EL (E6.5) No spont. tumourigenesis DMBA-induced 10% (splenocytes) 20% 29,31
Ubch10 overexpression n/a
Expression level dependent: 
40-80% (lymphoma, lung 
adenoma, lipoma and liver 
and skin)
Yes, but not significantly different 
compared to wild type
4-19% hi-lo, 5 mo (splenocytes); 
52-64% (lymphoma) 28-33% (WT 13%)  Yes










E CENPA EL (E6.5) VNODD ND
Chromosome missegregation in E6.5 
CENPA-/- embryos n/a
75
CENPB VNODD VNODD ND ND ND 76–78
CENPC EL (E3.5) VNODD ND Aberrant mitosis and micronuclei in early embryos n/a
79
Hec1 overexpression n/a 13% (lung), 26% (liver); 67 wk, 60 wk ND ND 25% Yes
13
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Table 1 List of various mouse models engineered to provoke CIN in vivo, with phenotypes and observed aneuploidy levels 
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17% females – (mammary);
mild brain abnormalities 
and altered behaviour
Tumour suppression upon TPA/DMBA 
treatment ND Increased (not quantified)
42
CENPE EL (<E7.5)
20% (lung, spleen); 19-
21 mo
Tumour suppression upon DMBA 
treatment or p19Arf loss 40% (splenocytes) 20% (up to 70% at high passage)
43,73
Mad1 EL 20% (lung); 18-20 mo Vinicristine-induced ND 10% 36
Mad2 EL 30% (lung); 18 mo ND ND 55% 11,74
Mad2 overexpression n/a 50% (lymphomas, lung & liver); 20 mo DMBA-induced Aneuploid tumours (not quantified) 50% Yes
34
Mps1 (T-cell restricted) VVNOD ~50% (lymphoma) 17 mo 100%, p53+/-; 5 mo >90% of cells aneuploid ND (Foijer et al., 2014)
Rae1 EL (E6.5) No spont. tumourigenesis DMBA-induced 10% (splenocytes) 20% 29,31
Ubch10 overexpression n/a
Expression level dependent: 
40-80% (lymphoma, lung 
adenoma, lipoma and liver 
and skin)
Yes, but not significantly different 
compared to wild type
4-19% hi-lo, 5 mo (splenocytes); 
52-64% (lymphoma) 28-33% (WT 13%)  Yes










E CENPA EL (E6.5) VNODD ND
Chromosome missegregation in E6.5 
CENPA-/- embryos n/a
75
CENPB VNODD VNODD ND ND ND 76–78
CENPC EL (E3.5) VNODD ND Aberrant mitosis and micronuclei in early embryos n/a
79
Hec1 overexpression n/a 13% (lung), 26% (liver); 67 wk, 60 wk ND ND 25% Yes
13
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Table 1 Continued. 
Group Gene -/- +/- Cancer predisposed 
(chemical or genetic collaboration)










Espl1 (separase) EL (E6.5) Epsl1+/H; VNODD 86% (lymphomas), p53
-/-; 4 mo – 50% 
(carcinoma), p53+/-




(mammary restricted) n/a 80% (mammary), 11 mo 100% (mammary), p53
+/-; 14 mo >80% (mammary tumours) ND 80







40-50% (haematoma, lung, 
fibrosarcoma, liver, vascu-
lar, pancreas); 24 mo
Resistance to 3MC and DEN induced 
fibrosarcomas and liver tumours 







n/a Tumour protective, pRb+/- ND 15% (WT 1%) 81,82
Pttg (securin) overex-
pression n/a
Enlarged pituitary; altered 
nuclear morphology >80% (pituitary), pRb




















(<E8.5) Intestinal tumours; 3 mo ND
Aneuploidy and abnormal mitosis in 
crypt cells Increased, not quantified
85–88
Incenp EL (3.5-8.5) VNODD ND
Abnormal nuclear morphology hy-
perdiploid content in E3.5 embryos n/a
89











(mammary restricted) n/a Increased p16 expression 45%, p53
-/- (mammary gland); 4.5 mo ND 13.6% 90,91
Plk1 EL (E10.5)
27.5% (lymphoma, lung); 
12.5-17.5 mo 100% (lymphoma, lung), p53
-/- 12% (splenocytes) ND  92
Plk4 overexpression (CNS 
restricted) n/a
Microcephaly, 100% 
post-natal lethality; <1 wk 100% lethality, p53
-/; 5 mo
31.7% centrosome amplification 
(neural stem cells); >60% aneuploidy 
of chr. 18 in p53-/-
ND 18
Usp44 VNODD
Usp44+/- 20%, Usp44-/- 
50%; 15 mo (lung, liver, 
lymphoma, sarcoma)






















S Ccnb2 (Cyclin B2) over-
expression n/a
>70% (lung, lymphoma, 
liver, lipoma); 14 mo
>80%, APC+/min; >80% (lung), DM-
BA-treatment 18% (splenocytes) 36% (ctrl. 16%)
(Nam and van 
Deursen, 2014)






ry); 12 mo ND ND ND  (Shima et al., 2007)
Tpx2 EL (E8.5) 53% (lymphoma, lung) no 18,3%, 16 wk; 27%, 90 wk (spleno-cytes) 48.9%, 90 wk (lymphomas)   
(Aguirre-Portolés et 
al., 2012)
EL = Embryonic lethal; VNODD = Viable, no overt developmental defects; ND = Not determined; n/a = Not applicable
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Table 1 Continued. 
Group Gene -/- +/- Cancer predisposed 
(chemical or genetic collaboration)
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40-50% (haematoma, lung, 
fibrosarcoma, liver, vascu-
lar, pancreas); 24 mo
Resistance to 3MC and DEN induced 
fibrosarcomas and liver tumours 







n/a Tumour protective, pRb+/- ND 15% (WT 1%) 81,82
Pttg (securin) overex-
pression n/a
Enlarged pituitary; altered 
nuclear morphology >80% (pituitary), pRb




















(<E8.5) Intestinal tumours; 3 mo ND
Aneuploidy and abnormal mitosis in 
crypt cells Increased, not quantified
85–88
Incenp EL (3.5-8.5) VNODD ND
Abnormal nuclear morphology hy-
perdiploid content in E3.5 embryos n/a
89











(mammary restricted) n/a Increased p16 expression 45%, p53
-/- (mammary gland); 4.5 mo ND 13.6% 90,91
Plk1 EL (E10.5)
27.5% (lymphoma, lung); 
12.5-17.5 mo 100% (lymphoma, lung), p53
-/- 12% (splenocytes) ND  92
Plk4 overexpression (CNS 
restricted) n/a
Microcephaly, 100% 
post-natal lethality; <1 wk 100% lethality, p53
-/; 5 mo
31.7% centrosome amplification 
(neural stem cells); >60% aneuploidy 
of chr. 18 in p53-/-
ND 18
Usp44 VNODD
Usp44+/- 20%, Usp44-/- 
50%; 15 mo (lung, liver, 
lymphoma, sarcoma)






















S Ccnb2 (Cyclin B2) over-
expression n/a
>70% (lung, lymphoma, 
liver, lipoma); 14 mo
>80%, APC+/min; >80% (lung), DM-
BA-treatment 18% (splenocytes) 36% (ctrl. 16%)
(Nam and van 
Deursen, 2014)






ry); 12 mo ND ND ND  (Shima et al., 2007)
Tpx2 EL (E8.5) 53% (lymphoma, lung) no 18,3%, 16 wk; 27%, 90 wk (spleno-cytes) 48.9%, 90 wk (lymphomas)   
(Aguirre-Portolés et 
al., 2012)
EL = Embryonic lethal; VNODD = Viable, no overt developmental defects; ND = Not determined; n/a = Not applicable
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